Ziv-aflibercept in metastatic colorectal cancer

Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Patel A, Sun W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/08234eea4bb64a41a57fa944c291856e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:08234eea4bb64a41a57fa944c291856e
record_format	dspace
spelling	oai:doaj.org-article:08234eea4bb64a41a57fa944c291856e2021-12-02T02:11:45ZZiv-aflibercept in metastatic colorectal cancer1177-5475https://doaj.org/article/08234eea4bb64a41a57fa944c291856e2013-12-01T00:00:00Zhttp://www.dovepress.com/ziv-aflibercept-in-metastatic-colorectal-cancer-a15286https://doaj.org/toc/1177-5475 Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen. Herein we review the role of tumor angiogenesis as the rationale for antiangiogenic therapy, the clinical data associated with ziv-aflibercept, and its current role as a treatment option compared to other antiangiogenic agents, such as bevacizumab and regorafenib. Keywords: aflibercept, angiogenesis, colorectal cancerPatel ASun WDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 13-25 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Patel A Sun W Ziv-aflibercept in metastatic colorectal cancer
description	Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become a conventional treatment option for patients with metastatic colorectal cancer. Ziv-aflibercept is a fusion protein which acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF); it was approved in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing fluoropyrimidine-based regimen. Herein we review the role of tumor angiogenesis as the rationale for antiangiogenic therapy, the clinical data associated with ziv-aflibercept, and its current role as a treatment option compared to other antiangiogenic agents, such as bevacizumab and regorafenib. Keywords: aflibercept, angiogenesis, colorectal cancer
format	article
author	Patel A Sun W
author_facet	Patel A Sun W
author_sort	Patel A
title	Ziv-aflibercept in metastatic colorectal cancer
title_short	Ziv-aflibercept in metastatic colorectal cancer
title_full	Ziv-aflibercept in metastatic colorectal cancer
title_fullStr	Ziv-aflibercept in metastatic colorectal cancer
title_full_unstemmed	Ziv-aflibercept in metastatic colorectal cancer
title_sort	ziv-aflibercept in metastatic colorectal cancer
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/08234eea4bb64a41a57fa944c291856e
work_keys_str_mv	AT patela zivafliberceptinmetastaticcolorectalcancer AT sunw zivafliberceptinmetastaticcolorectalcancer
_version_	1718402570225975296

Ziv-aflibercept in metastatic colorectal cancer

Ejemplares similares